logo
SEHK:9969 logo

InnoCare Pharma Community

SEHK:9969 Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

9969 logo
InnoCare Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts

Orelabrutinib Commercialization And ADC Pipeline Will Open New Markets

Key Takeaways Strong progress in drug commercialization and pipeline development suggests significant potential for future revenue growth and enhanced earnings. Strategic global expansion and innovative therapies aim to improve net margins and drive long-term revenue stability.
View narrative
HK$10.30
FV
6.3% undervalued intrinsic discount
33.33%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
10 days ago author updated this narrative